HomeCompareSNPHF vs QSR

SNPHF vs QSR: Dividend Comparison 2026

SNPHF yields 2.31% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNPHF wins by $23.5K in total portfolio value· pulled ahead in Year 2
10 years
SNPHF
SNPHF
● Live price
2.31%
Share price
$10.99
Annual div
$0.25
5Y div CAGR
33.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.2K
Annual income
$8,450.71
Full SNPHF calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — SNPHF vs QSR

📍 SNPHF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNPHFQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNPHF + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNPHF pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNPHF
Annual income on $10K today (after 15% tax)
$196.32/yr
After 10yr DRIP, annual income (after tax)
$7,183.10/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, SNPHF beats the other by $6,853.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNPHF + QSR for your $10,000?

SNPHF: 50%QSR: 50%
100% QSR50/50100% SNPHF
Portfolio after 10yr
$36.4K
Annual income
$4,419.29/yr
Blended yield
12.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

SNPHF
No analyst data
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNPHF buys
0
QSR buys
0
No recent congressional trades found for SNPHF or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNPHFQSR
Forward yield2.31%3.40%
Annual dividend / share$0.25$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.6%-0.8%
Portfolio after 10y$48.2K$24.7K
Annual income after 10y$8,450.71$387.88
Total dividends collected$24.8K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: SNPHF vs QSR ($10,000, DRIP)

YearSNPHF PortfolioSNPHF Income/yrQSR PortfolioQSR Income/yrGap
1$11,009$308.57$11,038$337.57$29.00QSR
2← crossover$12,203$424.14$12,156$345.43+$47.00SNPHF
3$13,645$587.05$13,359$352.69+$286.00SNPHF
4$15,419$819.56$14,654$359.36+$765.00SNPHF
5$17,655$1,156.39$16,045$365.45+$1.6KSNPHF
6$20,544$1,653.23$17,539$370.97+$3.0KSNPHF
7$24,384$2,402.01$19,143$375.96+$5.2KSNPHF
8$29,651$3,559.74$20,863$380.42+$8.8KSNPHF
9$37,131$5,404.68$22,708$384.39+$14.4KSNPHF
10$48,181$8,450.71$24,685$387.88+$23.5KSNPHF

SNPHF vs QSR: Complete Analysis 2026

SNPHFStock

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Full SNPHF Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this SNPHF vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNPHF vs SCHDSNPHF vs JEPISNPHF vs OSNPHF vs KOSNPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.